A feasibility study of high-dose hypofractionated carbon ion radiation therapy using four fractions for localized hepatocellular carcinoma measuring 3 cm or larger. (March 2019)

• Record Type: Journal Article
• Authors: Shibuya, Kei; Ohno, Tatsuya; Katoh, Hiroyuki; Okamoto, Masahiko; Shiba, Shintaro; Koyama, Yoshinori; Kakizaki, Satoru; Shirabe, Ken; Nakano, Takashi
• Is Part Of: Radiotherapy and oncology. Volume 132(2019)
• Page Start: 230
• Page End: 235
• Publication Date: 2019-03
• Subjects: Hepatocellular carcinoma -- Radiotherapy -- Carbon ion radiotherapy -- Hypofractionation; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2018.10.009
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: We investigated the feasibility of high-dose hypo-fractionated carbon ion radiotherapy (C-ion RT) for patients with hepatocellular carcinoma. C-ion RT using 60 Gy (RBE) in four fractions was safe and achieved promising local tumor control. The beneficial effect of C-ion RT using 60 Gy (RBE) in four fractions should be evaluated in further prospective trials. Abstract: Background and purpose: To evaluate the safety of carbon-ion radiotherapy (C-ion RT) using 60 Gy (relative biological effectiveness, RBE) in four fractions for patients with hepatocellular carcinoma (HCC). Materials and methods: The primary outcome was acute toxicities within 90 days. The secondary outcomes were late toxicities, local control, and progression-free survival and overall survival rates. The key inclusion criteria were as follows: (1) 3 cm or larger HCC without major vascular invasion and not adjacent to the alimentary tract; (2) Child–Pugh's grade A/B; and (3) without extrahepatic metastasis. Results: A total of 21 cases were analyzed between October 2012 and April 2016. The median follow-up period among the 17 survivors was 24.2 (range: 6.3–43.7) months. Grade 3 or higher acute toxicity was not observed, while three (14.3%) of the 21 patients experienced grade 3 late toxicities. The 1- and 2-year local control, progression-free survival, and overall survival rates were 100% and 92.3%, 81.0% and 50.0%, and 90.5% and 80.0%, respectively. Conclusion: C-ion RT using 60 Gy (RBE) in four fractions was safe and achieved promising local tumor control.